|Day Low/High||8.95 / 9.05|
|52 Wk Low/High||2.94 / 14.90|
Investors in Raptor Pharmaceuticals Corp. saw new options begin trading this week, for the October 19th expiration.
Early Launch Metrics Show Anticipated Strong PROCYSBI Demand
Prescription Claims Have Been Approved by Payors and Are Now Being Filled at Accredo Specialty Pharmacy
These under-$10 stocks look poised to trade higher from current levels.
Will insurers pay more for a orphan disease drug only because it's more convenient?
A list of stock-moving biotech catalysts includes FDA drug approvals, clinical trial results and closely-followed medical meetings.
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
Who will be the premier prognosticator of FDA drug approvals in 2013?
Levi & Korsinsky, LLP is investigating Raptor Pharmaceuticals Corp.
A list of stocks with drugs expecting FDA decisions in 2013
Clinical trials, drug launches and FDA approval decisions fill the early 2013 biotech calendar.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.